Lapatinib and Trastuzumab With or Without Endocrine Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mothaffar Rimawi, MD
Baylor Breast Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uab Cancer Center
Birmingham, Alabama, United States
- the University of Chicago
Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research
Baltimore, Maryland, United States
- Mayo Clinic Cancer Center
Rochester, Minnesota, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Baylor College of Medicine, Lester and Sue Smith Breast Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2008
- Primary completion
- 31 Jan 2011
- Completion
- 31 Jan 2014
- Last update posted
- 7 Nov 2019
- Registered enrollment
- 65
- Registry id
- NCT00548184
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.